Infect Chemother.  2025 Mar;57(1):138-147. 10.3947/ic.2024.0125.

The Mortality of Colistin Monotherapy vs. Colistin-Sulbactam for CarbapenemResistant Acinetobacter baumannii Pneumonia: A Propensity Score Analysis

• Cheh-Oh N
• Ungthammakhun C
• Changpradub D
• Santimaleeworagun W

• KMID: 2566768
• DOI: http://doi.org/10.3947/ic.2024.0125

Abstract

Background
This study compared the mortality rates within 30 days of 2 different doses of sulbactam (6 g and 9–12 g daily) when used in colistin (COL)-based treatment regimens and COL monotherapy for carbapenem-resistant Acinetobacter baumannii (CRAB).
Materials and Methods
This retrospective cohort study included 234 participants diagnosed with severe pneumonia due to CRAB infection at Phramongkutklao Hospital, Thailand, from July 1, 2011, to April 30, 2023. Participants were categorized into three groups: COL monotherapy, COL with 6 g of sulbactam daily (COL+S6g), and COL with 9–12 g of sulbactam daily (COL+SHD). Following the exclusion of patients with renal impairment (serum creatinine ≥1.5 mg/dl), a 1:2 propensity score (PS) matching was used to ensure comparable groups, with the COL group designated as the control. The matching variables included age, APACHE II scores, serum creatinine, intensive care units admission, and bacteremia. The number of participants in each group was as follows: 19 in COL, 32 in COL+S6g, and 38 in COL+SHD. The primary outcomes assessed were all-cause mortality rates at 7, 14, and 30 days. Kaplan–Meier survival curves and the Log-rank test were used to evaluate differences between groups, while multivariate Cox regression models were applied to determine the impact of treatment regimens.
Results
The unmatching PS analysis indicated that the COL+SHD regimen significantly reduces mortality compared to the COL regimen; hazard ratios (HR) were 0.18 (95% confidence interval [CI], 0.06–0.55) for 7-day mortality and 0.53 (95% CI,-0.29–0.97) for 30-day mortality. In addition, the COL+SHD regimen also lowered mortality more than the COL+S6g regimen within 7 days (HR, 0.29; 95% CI, 0.11–0.75). After PS matching, the COL+SHD regimen significantly reduced 7-day mortality compared to the COL regimen (adjusted HR, 0.24; 95% CI, -0.07–0.82). However, COL+S6g did not differ in mortality from either COL+SHD or COL for 7-day mortality. At 14 days and 30 days, there were no significant regimens to reduce mortality.
Conclusion
Combining COL+SHD effectively reduced death in 7 days from severe pneumonia in CRAB infection treatment.

Keyword

Colistimethate; Clinical outcome; Pneumonia; Polymyxin